A higher mutation stability was reported for IDH2 und DNMT3A mutations (95–100%) [13], indicating that persisting CH can contribute to relapse in both NPM1 mutated and wildtype patients [6, 12, 13]. This evidence concerns the gene IDH2 and cyclic hematopoiesis.